The cell cycle and cancer

Gareth H Williams; Kai Stoeber

doi:10.1002/path.3022

journal article Oct 28, 2011

The cell cycle and cancer

Gareth H Williams Kai Stoeber

The Journal of Pathology Vol. 226 No. 2 pp. 352-364 · Wiley

View at Publisher Save 10.1002/path.3022

Abstract

AbstractDeregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation. Gene expression profiling of these complex and redundant mitogenic pathways to identify prognostic and predictive signatures and their therapeutic targeting has, however, proved challenging. The cell cycle machinery, which acts as an integration point for information transduced through upstream signalling networks, represents an alternative target for diagnostic and therapeutic interventions. Analysis of the DNA replication initiation machinery and mitotic engine proteins in human tissues is now leading to the identification of novel biomarkers for cancer detection and prognostication, and is providing target validation for cell cycle‐directed therapies. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Topics

No keywords indexed for this article. Browse by subject →

References

135

[1]

10.1242/dev.110.4.1001

[2]

10.1242/dev.106.4.619

[3]

10.1016/j.ceb.2007.10.005

[4]

Murray A (1993)

[5]

10.1073/pnas.82.16.5365

[6]

10.1016/j.ccr.2005.12.026

[7]

10.1016/s0955-0674(97)80076-2

[8]

10.1038/35048096

[9]

Checkpoints: Controls That Ensure the Order of Cell Cycle Events

Leland H. Hartwell, Ted A. Weinert

Science 10.1126/science.2683079

[10]

10.1038/nrm1493

[11]

10.1038/nrm2163

[12]

10.1038/nrc2602

[13]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 10.1016/j.cell.2011.02.013

[14]

10.1101/gad.813200

[15]

Targeting cancer with small molecule kinase inhibitors

Jianming Zhang, Priscilla L. Yang, Nathanael S. Gray

Nature Reviews Cancer 10.1038/nrc2559

[16]

Freier K "Tissue microarray analysis reveals site‐specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma" Cancer Res (2003)

[17]

10.1038/sj.onc.1205206

[18]

10.1038/35106065

[19]

10.1038/35021093

[20]

10.1038/415530a

[21]

10.1038/nature06915

[22]

10.1016/s0140-6736(05)17866-0

[23]

10.1016/j.ejca.2006.11.018

[24]

10.1093/jnci/djr071

[25]

10.1016/s1470-2045(07)70346-7

[26]

10.1200/jco.2005.09.077

[27]

10.1038/nrc2173

[28]

10.1038/ncponc0558

[29]

The cancer genome

Michael R. Stratton, Peter J. Campbell, P. Andrew Futreal

Nature 10.1038/nature07943

[30]

10.1186/1476-4598-9-75

[31]

10.1200/jco.2009.23.2595

[32]

10.1038/ncponc0403

[33]

10.1200/jco.2009.26.5561

[34]

10.1007/s00268-010-0949-7

[35]

Batchelor T "The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study" Neuro‐Oncology (2010)

[36]

AstraZeneca. AstraZeneca provides update on cediranib (RECENTIN AZD2171) clinical development programme:http://www.astrazeneca‐us.com/search/?itemId = 2289031[accessed 27 February 2008].

[37]

AstraZeneca. AstraZeneca announces results of recentin HORIZON II Phase III trial in metastatic colorectal cancer:http://www.astrazeneca.com/Media/Press‐releases/Article/20100528–AstraZeneca‐Announces‐Results‐of‐Recentin‐HORIZON‐II‐[accessed 28 May 2010].

[38]

AstraZeneca. Phase II data contributes to understanding of cediranib in recurrent glioblastoma:http://astrazeneca‐usa.com/about‐astrazeneca‐us/newsroom/?itemId = 8889831[accessed 14 May 2010].

[39]

10.1073/pnas.95.25.14932

[40]

Williams G "Clinical applications of a novel mammalian cell‐free DNA replication system" Br J Cancer (1999)

[41]

10.1038/nrc1548

[42]

10.1038/nrc2500

[43]

10.1016/s0962-8924(01)02203-6

[44]

10.1016/j.cell.2005.09.019

[45]

10.1146/annurev.biochem.052308.103205

[46]

10.1146/annurev.genet.41.110306.130308

[47]

10.1016/s0959-437x(00)00158-1

[48]

10.1038/sj.embor.7400557

[49]

10.1016/s1097-2765(00)80110-0

[50]

10.1101/gad.1933010

Showing 50 of 135 references

Cited By

546

RETRACTED: miR-33b in human cancer: Mechanistic and clinical perspectives

Wenlong Zhang, Bincan Jiang · 2023

Biomedicine & Pharmacotherapy

In vitro anticancer activity of pyrano[3, 2-c]chromene derivatives with both cell cycle arrest and apoptosis induction

Ahmed M. El-Agrody, Ahmed M. Fouda · 2020

Medicinal Chemistry Research

Effects of Honey and Its Mechanisms of Action on the Development and Progression of Cancer

Omotayo Erejuwa, Siti Sulaiman · 2014

Molecules

Metrics

546

Citations

135

References

Details

Published: Oct 28, 2011
Vol/Issue: 226(2)
Pages: 352-364
License: View

Authors

Cite This Article

Gareth H Williams, Kai Stoeber (2011). The cell cycle and cancer. The Journal of Pathology, 226(2), 352-364. https://doi.org/10.1002/path.3022

The cell cycle and cancer

You May Also Like